FVFrancesco Vetri

Francesco Vetri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Vetri has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Chanannait Paisansathan

    Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, Chicago 60612, IL, USA

    9 shared publications
  • Dale A. Pelligrino

    Department of Anesthesiology, University of Illinois at Chicago, 1740 W. Taylor Street, M/C 515, Chicago, IL 60612, USA

    7 shared publications
  • Hao-Liang Xu

    Department of Anesthesiology, University of Illinois at Chicago, 1740 W. Taylor Street, M/C 515, Chicago, IL 60612, USA

    6 shared publications
  • Dale A. Pelligrino

    Neuroanesthesia Research Laboratory, University of Illinois at Chicago, Chicago, IL 60612, USA

    5 shared publications
  • Lizhen Mao

    Neuroanesthesia Research Laboratory University of Illinois Chicago Illinois USA

    5 shared publications
  • Haoliang Xu

    Department of Anesthesiology, University of Illinois at Chicago, 1740 W Taylor St, Chicago 60612, IL, USA

    4 shared publications

Latest Publications

  • Open Access

    Observations from the RESET clinical trial: A post-hoc per protocol analysis of clinical outcomes with percutaneous 60-day medial branch PNS in chronic low back pain

    by Sean Li, Zachary L. McCormick, Denise D. Lester, Michael J. DePalma, Christopher A. Gilmore, Jessica B. Jameson, Mehul J. Desai, Tristan E. Weaver, Shivanand P. Lad, Scott J. Davidoff, et al.

  • Open Access

    Modulation of microglial activation states by spinal cord stimulation in an animal model of neuropathic pain: Comparing high rate, low rate, and differential target multiplexed programming

    by William J Smith, David L Cedeño, Samuel M Thomas, Courtney A Kelley, Francesco Vetri, Ricardo Vallejo

    While numerous studies and patient experiences have demonstrated the efficacy of spinal cord stimulation as a treatment for chronic neuropathic pain, the exact mechanism underlying this therapy is still uncertain. Recent studies highlighting the importance of microglial cells in chronic pain and characterizing microglial activation transcriptomes have created a focus on microglia in pain research. Our group has investigated the modulation of gene expression in neurons and glial cells after spinal cord stimulation (SCS), specifically focusing on transcriptomic changes induced by varying SCS stimulation parameters. Previous work showed that, in rodents subjected to the spared nerve injury (SNI) model of neuropathic pain, a differential target multiplexed programming (DTMP) approach provided significantly better relief of pain-like behavior compared to high rate (HRP) and low rate programming (LRP). While these studies demonstrated the importance of transcriptomic changes in SCS mechanism of action, they did not specifically address the role of SCS in microglial activation. The data presented herein utilizes microglia-specific activation transcriptomes to further understand how an SNI model of chronic pain and subsequent continuous SCS treatment with either DTMP, HRP, or LRP affects microglial activation. Genes for each activation transcriptome were identified within our dataset and gene expression levels were compared with that of healthy animals, naïve to injury and interventional procedures. Pearson correlations indicated that DTMP yields the highest significant correlations to expression levels found in the healthy animals across all microglial activation transcriptomes. In contrast, HRP or LRP yielded weak or very weak correlations for these transcriptomes. This work demonstrates that chronic pain and subsequent SCS treatments can modulate microglial activation transcriptomes, supporting previous research on microglia in chronic pain. Furthermore, this study provides evidence that DTMP is more effective than HRP and LRP at modulating microglial transcriptomes, offering potential insight into the therapeutic efficacy of DTMP.


  • Pharmacologic blockade of vascular adhesion protein-1 lessens neurologic dysfunction in rats subjected to subarachnoid hemorrhage

    by Hao-Liang Xu, Maggie Garcia, Fernando Testai, Francesco Vetri, Alexandra Barabanova, Dale A. Pelligrino, Chanannait Paisansathan


  • Open Access

    BKCa channels as physiological regulators: a focused review

    by Francesco Vetri, Moumita Saha Roy Choudhury, Premanand Sundivakkam, Dale A. Pelligrino

    BKCa channels as physiological regulators: a focused review Francesco Vetri,1,* Moumita Saha Roy Choudhury,2 Dale A Pelligrino,1 Premanand Sundivakkam2,*1Department of Anesthesiology, 2Department of Medicine, University of Illinois at Chicago, IL, USA*These authors contributed equally to this work Large-conductance Ca2+- and voltage-gated big K+ (BKCa, MaxiK, or Slo1) channels are expressed in almost every cell of mammalian tissues and participate in a multitude of physiological processes such as vascular tone regulation, neuronal excitability, neurotransmitter release, neurovascular coupling, bladder tone regulation, urinary K+ excretion, and retinal circulation. BKCa channel is a tetramer of the pore-forming α-subunit encoded by a single gene, Slo. The BKCa-α-subunits are associated with the modulatory β-subunits, which contribute to the functional diversity of the channel. BKCa channels sense and regulate membrane voltage and intracellular Ca2+, which then modulates several cell signaling and metabolic pathways. This review focuses on the main physiologic roles of BKCa channels and the pathogenesis of diseases associated with their loss or malfunction. The mechanistic information highlighted in this review is aimed to enhance the understanding of the unique and diverse roles of BKCa channels in various physiological and pathophysiological phenomena.Keywords: neurovascular coupling, large conductance calcium, Ca2+-activated potassium channels, BKCa channel physiology


  • Complex modulation of the expression of PKC isoforms in the rat brain during chronic type 1 diabetes mellitus

    by Francesco Vetri, Rafael Chavez, Hao-Liang Xu, Chanannait Paisansathan, Dale A. Pelligrino


  • Open Access

    Post‐ischemic vascular adhesion protein‐1 inhibition provides neuroprotection in a rat temporary middle cerebral artery occlusion model

    by Jittiya Watcharotayangul, Lizhen Mao, Haoliang Xu, Francesco Vetri, Verna L. Baughman, Chanannait Paisansathan, Dale A. Pelligrino

    We examined the neuroprotective efficacy associated with post‐ischemic vascular adhesion protein‐1 (VAP‐1) blockade in rats subjected to transient (1 h) middle cerebral artery occlusion (MCAo). We compared saline‐treated control rats to rats treated with a highly selective VAP‐1 inhibitor, LJP‐1586 [Z‐3‐fluoro‐2‐(4‐methoxybenzyl) allylamine hydrochloride]. Initial intraperitoneal LJP‐1586 (or saline control) treatments were delayed until 6 h or 12 h reperfusion. At 72‐h reperfusion, LJP‐1586‐treated rats displayed 51% and 33% smaller infarct volumes, relative to their controls, in the 6‐ and 12‐h treatment groups, respectively. However, only in the 6‐h treatment group was the infarct volume reduction significant (p < 0.05). On the other hand, we observed significantly improved neurologic functions in both 6‐ and 12‐h treatment groups, versus their matched controls (p < 0.05). Also, the effect of 6‐h LJP‐1586 treatment on post‐ischemic leukocyte trafficking in pial venules overlying the ischemic cortex was evaluated using intravital microscopy. These experiments revealed that: 1) LJP‐1586 did not affect intravascular leukocyte (largely neutrophil) adhesion, at least out to 12‐h reperfusion; and 2) the onset of neutrophil extravasation, which occurred between 6–8‐h reperfusion in control rats, was prevented by LJP‐1586‐treatment. In conclusion, in rats subjected to transient MCAo, selective VAP‐1 pharmacologic blockade provided neuroprotection, with a prolonged therapeutic window of 6–12‐h reperfusion.


  • Impairment of neurovascular coupling in type 1 diabetes mellitus in rats is linked to PKC modulation of BKCa and Kir channels

    by Francesco Vetri, Haoliang Xu, Chanannait Paisansathan, Dale A. Pelligrino

    We hypothesized that chronic hyperglycemia has a detrimental effect on neurovascular coupling in the brain and that this may be linked to protein kinase C (PKC)-mediated phosphorylation. Therefore, in a rat model of streptozotocin-induced chronic type 1 diabetes mellitus (T1DM), and in nondiabetic (ND) controls, we monitored pial arteriole diameter changes during sciatic nerve stimulation and topical applications of the large-conductance Ca2+-operated K+ channel (BKCa) opener, NS-1619, or the K+ inward rectifier (Kir) channel agonist, K+. In the T1DM vs. ND rats, the dilatory response associated with sciatic nerve stimulation was decreased by ∼30%, whereas pial arteriolar dilations to NS-1619 and K+ were largely suppressed. These responses were completely restored by the acute topical application of a PKC antagonist, calphostin C. Moreover, the suffusion of a PKC activator, phorbol 12,13-dibutyrate, in ND rats was able to reproduce the vascular reactivity impairments found in T1DM rats. Assay of PKC activity in brain samples from T1DM vs. ND rats revealed a significant gain in activity only in specimens harvested from the pial and superficial glia limitans tissue, but not in bulk cortical gray matter. Altogether, these findings suggest that the T1DM-associated impairment of neurovascular coupling may be mechanistically linked to a readily reversible PKC-mediated depression of BKCa and Kir channel activity.


  • ATP hydrolysis pathways and their contributions to pial arteriolar dilation in rats

    by Francesco Vetri, Haoliang Xu, Lizhen Mao, Chanannait Paisansathan, Dale A. Pelligrino

    ATP is thought to be released to the extracellular compartment by neurons and astrocytes during neural activation. We examined whether ATP exerts its effect of promoting pial arteriolar dilation (PAD) directly or upon conversion (via ecto-nucleotidase action) to AMP and adenosine. Blockade of extracellular direct ATP to AMP conversion, with ARL-67156, significantly reduced sciatic nerve stimulation-evoked PADs by 68%. We then monitored PADs during suffusions of ATP, ADP, AMP, and adenosine in the presence and absence of the following: 1) the ecto-5′-nucleotidase inhibitor α,β-methylene adenosine 5′-diphosphate (AOPCP), 2) the A2 receptor blocker ZM 241385, 3) the ADP P2Y1 receptor antagonist MRS 2179, and 4) ARL-67156. Vasodilations induced by 1 and 10 μM, but not 100 μM, ATP were markedly attenuated by ZM 241385, AOPCP, and ARL-67156. Substantial loss of reactivity to 100 μM ATP required coapplications of ZM 241385 and MRS 2179. Dilations induced by ADP were blocked by MRS 2179 but were not affected by either ZM 241385 or AOPCP. AMP-elicited dilation was partially inhibited by AOPCP and completely abolished by ZM 241385. Collectively, these and previous results indicate that extracellular ATP-derived adenosine and AMP, via A2 receptors, play key roles in neural activation-evoked PAD. However, at high extracellular ATP levels, some conversion to ADP may occur and contribute to PAD through P2Y1 activation.


  • Purinergic mechanisms in gliovascular coupling

    by Dale A. Pelligrino, Francesco Vetri, Hao-Liang Xu